Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Disease and Therapy Review: Hepatitis C Timely Data Resources, Inc., Jan 2007, Pages: 7   Description     Table of Contents        Enquire before Buying    Send to a Friend   The Hepatitis C Disease and Therapy Review provides incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatments. Dosing information and treatment costs are provided for Peg-Intron, Pegasys, Rebetol, Copegus, and generic ribavirin capsules. General information on sales of peginterferon and ribavirin is provided. Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by a senior market research team. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Langes Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites.  Sources and references are provided.   Customers who bought this item also bought Treatment Algorithms 2002: Hepatitis B and C Drugs of Tomorrow 2001: Hepatitis - The Succession of New Generation Therapies Disease and Therapy Review: Hepatitis B Antiviral Resistance: Innovation Reshaping Viral Treatment, 2001 Edition New Pegylated Interferons: Assessing the Impact of the New Longer Acting Interferons on the Hepatitis C Market Market Dynamics 2001: Hepatitis B&C - The Succession of New Generation Therapies Disease & Therapy Review (DTR) Executive Market Summaries Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster